文献速递胃肠动力与功能性疾病

英国罗马IV或罗马III标准定义的肠易激综合征直接医疗成本

Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom.
PubMed 文献 · Aliment Pharmacol Ther · 2022-05-01

基于英国752例罗马IV和995例罗马III肠易激综合征(IBS)成人的数据,计算人均年直接医疗成本并估算全国年度总成本。使用阿片类药物、症状更严重、病程更短、生活质量更低及抑郁、躯体化、胃肠道症状特异性焦虑评分更高者成本更高。

要点

  • 使用阿片类药物者人均年成本907.90英镑 vs 未使用者470.58英镑(p < 0.001)。

核心结论

  • 使用罗马IV标准定义IBS时,英国卫生服务管理IBS的人均年直接成本超过12亿英镑;使用罗马III标准时超过20亿英镑。
  • 使用阿片类药物、IBS症状更严重、生活质量更低、病程更短以及抑郁、躯体化、胃肠道症状特异性焦虑水平更高者,人均年直接医疗成本更高。
  • 有效多学科管理IBS对减轻医疗系统经济负担很重要。

研究设计与样本

  • 收集英国罗马IV或罗马III标准定义的IBS成人的 demographic、胃肠道和心理症状、生活质量及医疗服务使用数据。
  • 计算每人每年IBS直接医疗成本均值,并结合同期IBS患病率数据和人口普查数据估算IBS年度直接成本。
  • 分析成本较高的预测因素。
  • 样本包括752例罗马IV IBS个体和995例罗马III IBS个体。

主要发现

  • 752例罗马IV IBS个体的人均年直接成本为556.65英镑(SD 1023.92)。
  • 995例罗马III IBS个体的人均年直接成本为474.16英镑(SD 897.86)。
  • 罗马IV IBS个体中,使用阿片类药物者人均年成本907.90英镑 vs 未使用者470.58英镑(p < 0.001)。
  • 罗马IV IBS个体中,症状更严重者成本更高(趋势p < 0.001);病程1年者人均年成本1227.14英镑 vs 病程>5年者501.60英镑(p = 0.002);生活质量更低者成本更高(趋势p < 0.001);抑郁、躯体化和胃肠道症状特异性焦虑评分更高者成本更高(各项趋势P < 0.001)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous studies have demonstrated a substantial economic impact of irritable bowel syndrome (IBS). AIMS: To provide contemporaneous estimates of direct healthcare costs of IBS in the United Kingdom. METHODS: We collected demographic, gastrointestinal and psychological symptoms, quality of life and healthcare usage data from adults with Rome IV or Rome III IBS in the United Kingdom. We calculated the mean annual direct healthcare costs of IBS per person and used contemporaneous IBS prevalence data, together with census data, to estimate annual direct costs of IBS. We also examined predictors of higher costs. RESULTS: The mean annual direct cost of IBS per person among 752 individuals with Rome IV IBS was £556.65 (SD £1023.92) and £474.16 (SD £897.86) for 995 individuals with Rome III IBS. We estimate the annual direct healthcare cost of IBS in the United Kingdom is £1.27 billion if the Rome IV criteria are used to define IBS, and £2.07 billion using Rome III. Among individuals with Rome IV IBS, mean annual costs were higher in those with opiate use (£907.90 vs £470.58, p < 0.001), more severe symptoms (p < 0.001 for trend), a shorter duration of IBS (1 year, £1227.14 vs >5 years £501.60, p = 0.002), lower quality of life (p < 0.001 for trend), and higher depression, somatisation and gastrointestinal symptom-specific anxiety scores (P < 0.001 for trend for all). CONCLUSION: We estimate annual direct healthcare costs of IBS of between £1.3 and £2 billion in the United Kingdom. Using data from over 750 individuals we provide a contemporaneous estimate of the mean annual direct costs of managing IBS to the United Kingdom health service of more than £1.2 billion, if the Rome IV criteria are used to define IBS, and more than £2 billion with Rome III. Mean annual direct healthcare costs were higher in those who used opiates, and those with more severe IBS symptoms, lower quality of life, a shorter duration of disease, and higher levels of depression, somatisation, and gastrointestinal symptom‐specific anxiety. Effective multidisciplinary management of IBS is important to reduce the economic burden that the condition represents to the healthcare system.[Image: see text]

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Goodoory VC, Ng CE, Black CJ, et al. Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom. Aliment Pharmacol Ther. 2022. PMID: 35491477. doi:10.1111/apt.16939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。